

# Martin Eklund

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/15625/publications.pdf>

Version: 2024-02-01

98  
papers

4,587  
citations

201674

27  
h-index

118850

62  
g-index

103  
all docs

103  
docs citations

103  
times ranked

6814  
citing authors

#	ARTICLE	IF	CITATIONS
1	Artificial Intelligence in Magnetic Resonance Imaging-based Prostate Cancer Diagnosis: Where Do We Stand in 2021?. <i>European Urology Focus</i> , 2022, 8, 409-417.	3.1	21
2	Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 165-173.	3.9	4
3	Mortality in men with castration-resistant prostate cancer: A long-term follow-up of a population-based real-world cohort. <i>BJUI Compass</i> , 2022, 3, 173-183.	1.3	12
4	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. <i>Nature Medicine</i> , 2022, 28, 154-163.	30.7	143
5	Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. <i>Nature Medicine</i> , 2022, 28, 9-11.	30.7	17
6	Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>European Urology</i> , 2022, 82, 12-19.	1.9	4
7	Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer. <i>European Urology Focus</i> , 2022, 8, 1617-1621.	3.1	7
8	A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. <i>European Urology Open Science</i> , 2022, 38, 32-39.	0.4	2
9	Detection of perineural invasion in prostate needle biopsies with deep neural networks. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 73-82.	2.8	7
10	Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. <i>Scandinavian Journal of Urology</i> , 2022, 56, 169-175.	1.0	1
11	Association of 5 $\alpha$ -Reductase Inhibitors With Prostate Cancer Mortality. <i>JAMA Oncology</i> , 2022, 8, 1019.	7.1	18
12	Impact of a Deep Learning Model for Predicting Mammographic Breast Density in Routine Clinical Practice. <i>Journal of the American College of Radiology</i> , 2022, 19, 1021-1030.	1.8	2
13	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. <i>Bioinformatics</i> , 2022, 38, 3462-3469.	4.1	9
14	Using deep learning to detect patients at risk for prostate cancer despite benign biopsies. <i>IScience</i> , 2022, 25, 104663.	4.1	5
15	Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 1797-1804.	2.2	10
16	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. <i>Modern Pathology</i> , 2021, 34, 660-671.	5.5	84
17	Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 120-127.	3.9	5
18	Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 457-464.	3.9	1

#	ARTICLE	IF	CITATIONS
19	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). Journal of the National Cancer Institute, 2021, 113, 632-640.	6.3	9
20	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
21	The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. European Urology Open Science, 2021, 24, 43-51.	0.4	2
22	Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. European Urology Open Science, 2021, 24, 11-16.	0.4	2
23	Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1109-1116.	2.8	7
24	Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 1588.	3.7	1
25	Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. European Urology Focus, 2021, 7, 546-553.	3.1	16
26	Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. Journal of Clinical Oncology, 2021, 39, 1899-1908.	1.6	33
27	Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scandinavian Journal of Urology, 2021, 55, 299-306.	1.0	4
28	Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies – Current Status and Next Steps. European Urology Focus, 2021, 7, 687-691.	3.1	18
29	OpenPhi: an interface to access Philips iSyntax whole slide images for computational pathology. Bioinformatics, 2021, 37, 3995-3997.	4.1	3
30	The emerging role of artificial intelligence in the reporting of prostate pathology. Pathology, 2021, 53, 565-567.	0.6	0
31	The WISDOM study: a new approach to screening can and should be tested. Breast Cancer Research and Treatment, 2021, 189, 593-598.	2.5	19
32	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. New England Journal of Medicine, 2021, 385, 908-920.	27.0	184
33	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1240-1249.	10.7	83
34	Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. European Urology Oncology, 2020, 3, 640-647.	5.4	15
35	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	10.7	364
36	Comparison of a Deep Learning Risk Score and Standard Mammographic Density Score for Breast Cancer Risk Prediction. Radiology, 2020, 294, 265-272.	7.3	98

#	ARTICLE	IF	CITATIONS
37	Response to Carter et al.. JNCI Cancer Spectrum, 2020, 4, pkaa016.	2.9	0
38	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. Journal of Clinical Pathology, 2020, 73, 630-635.	2.0	9
39	Range of Radiologist Performance in a Population-based Screening Cohort of 1 Million Digital Mammography Examinations. Radiology, 2020, 297, 33-39.	7.3	21
40	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey. PLoS ONE, 2020, 15, e0238217.	2.5	349
41	External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. JAMA Oncology, 2020, 6, 1581.	7.1	148
42	Effect of artificial intelligence-based triaging of breast cancer screening mammograms on cancer detection and radiologist workload: a retrospective simulation study. The Lancet Digital Health, 2020, 2, e468-e474.	12.3	122
43	The utility of artificial intelligence in the assessment of prostate pathology. Histopathology, 2020, 76, 790-792.	2.9	9
44	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	2.8	20
45	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials, 2020, 21, 579.	1.6	16
46	Association between PSA density and prostate cancer in men without significant MRI lesions. BJU International, 2020, 125, 763-764.	2.5	8
47	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA <math>\leq 3\text{ ng/ml}</math>. Scandinavian Journal of Urology, 2020, 54, 1-6.	1.0	11
48	The economic burden of prostate cancer - a Swedish prevalence-based register study. BMC Health Services Research, 2020, 20, 448.	2.2	19
49	Title is missing!. , 2020, 15, e0238217.		0
50	Title is missing!. , 2020, 15, e0238217.		0
51	Title is missing!. , 2020, 15, e0238217.		0
52	Title is missing!. , 2020, 15, e0238217.		0
53	Prognostic factors for digital range of motion after intrasynovial flexor tendon injury and repair: Long-term follow-up on 273 patients treated with active extension-passive flexion with rubber bands. Journal of Hand Therapy, 2019, 32, 328-333.	1.5	11
54	Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. BMC Urology, 2019, 19, 73.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The importance of study design in the application of artificial intelligence methods in medicine. <i>Npj Digital Medicine</i> , 2019, 2, 101.	10.9	2
56	Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. <i>JAMA Network Open</i> , 2019, 2, e1914689.	5.9	16
57	Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. <i>BMJ Open</i> , 2019, 9, e027816.	1.9	11
58	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. <i>PLoS ONE</i> , 2019, 14, e0218280.	2.5	7
59	A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019, 2, 490-496.	5.4	13
60	The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. <i>BMJ Open</i> , 2019, 9, e027958.	1.9	15
61	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <i>PLoS ONE</i> , 2019, 14, e0211918.	2.5	10
62	The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 137-142.	3.9	20
63	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , 2019, 144, 1195-1204.	5.1	31
64	Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Gr�nberg, Martin Eklund, Wolfgang Pickler, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>Eur Urol</i> 2018;74:722-728. <i>European Urology</i> , 2019, 75, e104-e105.	1.9	0
65	Response to Walsh. <i>Journal of the National Cancer Institute</i> , 2019, 111, 748-748.	6.3	0
66	The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>European Urology</i> , 2018, 74, 204-210.	1.9	68
67	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 57-63.	3.9	134
68	Reply to Ola Bratt and Anna �fverholm's Letter to the Editor re: Peter Str�m, Tobias Nordstr�m, Henrik Gr�nberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2017.12.028">https://doi.org/10.1016/j.eururo.2017.12.028</a> . <i>European Urology</i> , 2018, 74, e10-e11.	1.9	0
69	Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. <i>Breast Cancer Research</i> , 2018, 20, 14.	5.0	8
70	Risk of Prostate Cancer in Men Treated With 5�-Reductase Inhibitors��A Large Population-Based Prospective Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1216-1221.	6.3	27
71	Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. <i>European Urology Focus</i> , 2018, 4, 385-387.	3.1	9
72	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50��69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , 2018, 4, 707-710.	3.1	42

#	ARTICLE	IF	CITATIONS
73	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018, 142, 741-746.	5.1	29
74	The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky067.	2.9	25
75	Towards Next-generation Urine-based Prostate Cancer Risk Stratification. <i>European Urology</i> , 2018, 74, 739-740.	1.9	2
76	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , 2018, 74, 722-728.	1.9	70
77	Predictors of participation in risk-based prostate cancer screening. <i>PLoS ONE</i> , 2018, 13, e0200409.	2.5	12
78	Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139-46. <i>European Urology</i> , 2018, 74, e35-e36.	1.9	2
79	Effects of pre-notification, invitation length, questionnaire length and reminder on participation rate: a quasi-randomised controlled trial. <i>BMC Medical Research Methodology</i> , 2018, 18, 3.	3.1	27
80	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
81	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
82	E-Science technologies in a workflow for personalized medicine using cancer screening as a case study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 950-957.	4.4	4
83	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw290.	6.3	171
84	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. <i>European Urology Focus</i> , 2017, 3, 526-528.	3.1	14
85	Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study. Grönberg H et al. <i>Lancet Oncology</i> . 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. <i>World Journal of Urology</i> , 2017, 35, 895-896.	2.2	0
86	Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. <i>BMC Urology</i> , 2017, 17, 92.	1.4	3
87	The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 394-394.	27.6	7
88	Population-based screening for cancer: hope and hype. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 550-565.	27.6	98
89	Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw165.	6.3	13
90	Detection of ductal carcinoma in situ and subsequent interval cancers. <i>BMJ, The</i> , 2016, 352, i551.	6.0	4

#	ARTICLE	IF	CITATIONS
91	Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 45-51.	1.8	39
92	Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) $\geq 7$ prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 284-284.	1.6	0
93	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015, 75, 1467-1474.	2.3	54
94	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , 2015, 68, 139-146.	1.9	156
95	Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. <i>Lancet Oncology</i> , The, 2015, 16, 1667-1676.	10.7	308
96	A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of $1-3$ ng/ml. <i>European Urology</i> , 2014, 65, 1184-1190.	1.9	32
97	Aggregate Cost of Mammography Screening in the United States: Comparison of Current Practice and Advocated Guidelines. <i>Annals of Internal Medicine</i> , 2014, 160, 145.	3.9	79
98	Prostate Cancer Screening Using a Combination of Risk-Prediction, Magnetic Resonance Imaging and Targeted Prostate Biopsies: A Randomised Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2